FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Norman DeLisle on LinkedIn: Michigan's seven-day average highest

Medical Device News Update - August 2023 - Let's Talk Risk!

FDA's Fast-Track for Rexulti Raises Concerns

FDA rules Otsuka marketing claim overstates Rexulti efficacy

FDA Faces Hard Decisions After Fast-Tracking Unproven Drugs

FDA's accelerated drug approvals often lack confirmatory evidence

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Medicare coverage debates amplify as FDA approves Rexulti for

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

vtgn20220331_10k.htm

Pristiq: Side effects and what to do about them

Pharmaceutical payments to psychiatrists and betrayal of the

SEC Filing Vistagen Therapeutics, Inc

Accelerated Change: Understanding the FDA's Expedited Pathways

FDA's accelerated drug approvals often lack confirmatory evidence